Table 1.

Basic information of the included randomized controlled trials

Author year	Country	Trial design	Sample		Mean age		Baseline disease	Intervention		Dosage	Duration	Outcomes
			T	C	T	C		T	C	mg/d	/w
Adler, A. J.,1997 [20]	Canada	parallel	11	11	45.9	45.4	hyperlipidemia	GT	placebo	900	12	TG,TC,LDL,HDL
Aslani, N.,2016 [21]	Iran	parallel	27	28	45.3	39.3	hyperlipidemia	RG	none		8	BMI,TG,TC,LDL,HDL
Auer 1990 [22]	Germany	parallel	24	23	NR	NR	hypertension	GT	placebo	600	12	SBP,DBP
Byrne, DJ.,1999 [23]	UK	parallel	20	11	NR	NR	hyperlipidemia	GT	placebo	900	24	TG,TC,LDL,HDL
Gardner, CD.,2001 [24]	USA	parallel	16	18	50.2	51.6	hyperlipidemia	GT	placebo	999	12	TG,TC,LDL,HDL
Higashikawa, F., 2012 [25]	Japan	parallel	28	26	52	51.4	hyperlipidemia	PG	placebo	900	12	BMI,TG,TC,LDL,HDL,FBG
Isaacsohn, JL.,1998 [26]	USA	parallel	24	18	58	57.4	hyperlipidemia	GT	placebo	900	12	BMI,TG,TC,LDL,HDL,SBP,DBP
Jain, AK.,1993 [27]	USA	parallel	20	22	48	55	hyperlipidemia	GT	placebo	900	12	TG,TC,LDL,HDL,FBG,SBP,DBP
Jung, ES.,2014 [28]	Korea	parallel	28	27	50.13	50.83	hyperlipidemia	AGE	placebo		12	TG,TC,LDL,HDL
Kannar, D.,2001 [29]	Australia	parallel	19	22	52.6	57.4	hyperlipidemia	GT	placebo	800	12	TG,TC,LDL,HDL
Nakasone,Yasushi, 2013 [30]	Japan	parallel	19	21	58	59	hypertension	GT	placebo	188	12	SBP,DBP
Peleg, A.,2003 [31]	Israel	parallel	13	20	52.4	54.7	hyperlipidemia	GT	placebo		16	TG,TC,LDL,HDL
Riad, Karin,2018 [32]	Australia	parallel	23	26	62.8	61.9	hypertension	AGE	placebo	2400	12	WC,BMI,TG,LDL,HDL,FBG,SBP,DBP
Sangouni, Abbas A,2020 [33]	Iran	parallel	45	43	45.2	44.2	NAFLD	GT	placebo	1600	12	WC,BMI,TG,TC,LDL,HDL
Sangouni, Abbas A,2021 [14]	Iran	parallel	42	42	46.9	44.6	MetS	GT	placebo	1600	12	TG,TC,LDL,HDL
Sharifi, F.,2010 [34]	Iran	parallel	20	20	47.9	50.5	MetS	GT	placebo	1800	6	WC,BMI,TG,TC,HDL,FBG,SBP,DBP
Simons, LA.,1995 [35]	Australia	crossover	12	17	53.6	53.6	hyperlipidemia	GT	placebo	900	12	TG,TC,LDL,HDL,SBP,DBP
Superko, HR. 2000 [36]	USA	parallel	25	25	53	53	hyperlipidemia	GT	placebo	900	12	SBP,DBP
Valls, RM.,2022 [37]	Spain	crossover	32	34	53.7	52.7	hyperlipidemia	AGE	placebo	250	6	SBP,DBP

T Treatment group, C Control group, NR: not reported, NAFLD Non-alcoholic fatty liver disease, MetS Metabolic syndrome, GT Garlic tablet, RG Row garlic, PG Processed garlic, AGE Aged garlic extract, WC Waist circumference, BMI Body mass index, TG Triglycerides, TC Total cholesterol, LDL-c Low-density lipoprotein cholesterol, HDL-c High-density lipoprotein cholesterol, FBG Fasting blood glucose, SBP Systolic blood pressure, DBP Diastolic blood pressure